In this study, we demonstrate that metformin can decrease tumor hypoxia and consequently increase radiation response. This provides a scientific rationale for combining metformin with radiotherapy in the clinic. Metformin is commonly prescribed as first line of treatment for patients with type 2 diabetes. It is generally well tolerated and already taken by numerous diabetic patients undergoing radiotherapy for cancer. Introduction of metformin to non-diabetic patients receiving radiation treatment is therefore of high feasibility, and could counteract tumor hypoxia that currently limits treatment efficacy. Identification of a novel mechanism by which metformin can improve radiation response will guide future biomarker evaluation and patient selection. 
Statement of Translational Relevance
In this study, we demonstrate that metformin can decrease tumor hypoxia and consequently increase radiation response. This provides a scientific rationale for combining metformin with radiotherapy in the clinic. Metformin is commonly prescribed as first line of treatment for patients with type 2 diabetes. It is generally well tolerated and already taken by numerous diabetic patients undergoing radiotherapy for cancer. Introduction of metformin to non-diabetic patients receiving radiation treatment is therefore of high feasibility, and could counteract tumor hypoxia that currently limits treatment efficacy. Identification of a novel mechanism by which metformin can improve radiation response will guide future biomarker evaluation and patient selection.
Introduction
The presence of tumor hypoxia is a negative prognostic factor in tumors treated with curative intent by radiotherapy (RT) across multiple sites, including squamous cell carcinoma of the head and neck (1) and prostate carcinoma (2) . Tumor cells located further than ~150µm from vessels experience 'diffusion-limited' hypoxia as oxygen is consumed by the tumor cells more proximal to the vessels (3) . Severely hypoxic yet viable cells are well documented to surround necrotic volumes (4) , and these hypoxic cells are resistant to ionizing radiation (IR) (3) . Several randomized clinical trials have shown the potential for improving RT efficacy by modifying the tumor microenvironment (5, 6) . In these trials, attempts to increase tumor oxygenation prior to therapy were made using hyperbaric oxygen or an oxygen-rich gas like carbogen (95% O 2 , 5% CO 2 ) in combination with systemic administration of vasodilating agents. In spite of positive results (5, 6) , these strategies have not gained clinical traction due to practical limitations, toxicity and relatively modest clinical benefit (7) .
An alternative strategy to achieve improved tumor oxygenation is to decrease cellular oxygen consumption; a rational choice given that oxygen gradients arise from tumor cell respiration. Mathematical modeling suggests that decreasing oxygen consumption could be significantly more efficient at improving tumor oxygenation than increasing oxygen supply (8) .
There is therefore ample rationale for combining pharmaceutical agents that decrease oxygen consumption with curative RT. This strategy has been explored in vitro, where a variety of respiration inhibitors have been shown to radiosensitize 3-D spheroid models that contain viable hypoxic radioresistant cells in their interior (9) (10) (11) (12) . The respiration inhibitors metaiodobenzylguanadine and arsenic trioxide have also been shown to increase radiation response in experimental tumor models (13, 14) , but these agents are infrequently prescribed and may be associated with toxicities when combined with RT.
Metformin is a commonly-prescribed biguanide used as a first-line treatment for type II diabetes. It efficiently and safely lowers blood glucose levels, and subsequently insulin, by inhibiting liver gluconeogenesis. Metformin's primary mechanism of action is considered to be direct inhibition of complex I activity in the mitochondrial electron transport chain (ETC) (15) (16) (17) . The ETC provides cellular ATP by transferring electrons from substrates provided by the citric acid cycle to molecular oxygen. Given that metformin is a well-tolerated drug already consumed by millions of diabetic patients undergoing RT, we hypothesized that metformin's activity as a respiration inhibitor could lead to increases in tumor RT response through inhibition of tumor cell oxygen consumption and improved tumor oxygenation. This would constitute a novel mechanism in which tumor radioresponse is improved secondary to metabolic remodeling, rather than a change in the intrinsic radiosensitivity of the tumor cell.
Methods

Cell lines and culture
LNCaP (CRL-1740 ™ ) prostate carcinoma and HCT116 (CCL-247™) colorectal carcinoma cells were from ATCC. The SCC-74B cell line was a generous gift from Dr. R.
Grenman at Turku University Hospital (Finland), established from a squamous cell carcinoma of the tongue metastasized to a neck lymph node. The POP-092S cell line was created at Princess Margaret Cancer Center from a primary xenograft established from an adenocarcinoma of the sigmoid colon. LNCaP, HCT116 and SCC-74B cells were grown as adherent monolayers and in MEM:F15, all supplemented with 10% fetal bovine serum (FBS) (all Gibco). POP-092S cells were grown in suspension in growth media to enrich for stem cells (18) . Oxygen consumption was measured using a Seahorse XF96 Extracellular Flux Bioanalyzer (Seahorse Bioscience).
Irradiation and clonogenic survival
Cells were irradiated using a 137 Cs Nordion Gammacell unit at a dose rate of 1.03Gy/min.
Metformin was present for 30 minutes before, and 1 hour after, irradiation. Cells were then trypsinized and single-cells plated for clonogenic survival at low density in triplicate. After 14 days, colonies were fixed, stained (0.2% methylene blue in 80% ethanol) and counted if containing more than 50 cells. Surviving fraction was calculated as the number of colonies divided by the number of seeded cells in the treated population, corrected by the same ratio for the untreated.
Xenograft establishment and growth
All animal experiments were performed under protocols approved by the Ontario Cancer Institute's Animal Care Committee, according to the regulations of the Canadian Council on Animal Care. HCT116 and POP-092S donor tumors were grown in the right biceps femoris muscle and under the left renal capsule, respectively. Tumor fragments measuring 2.0 mm were implanted subcutaneously into the right flank of syngeneic mice. SCID mice were used for all experiments except tumor growth delay after irradiation, where we used non-radiosensitive athymic CD-1 nude mice. Tumor growth was monitored by caliper measurements 3 times a week. All surgical procedures and tumor imaging were carried out under anesthesia (3% Figure S1A ). A threshold for background was applied to each individual stain signal and subsequently either the average intensity or a binarized fractional positive area ( Figure S1B ) was calculated.
Flow cytometry
Tumors were disaggregated using DNAse I, Streptomyces griseus protease and collagenase IX, filtered, fixed and permeabilized using fomaldehyde and Triton X-100 (all Sigma). Cells were blocked with 10% skim milk, 1.5% lipid-free albumin, 5% mouse serum and stained with FITC-anti-pimonidazole, Cy5-conjugated antibody against EF5 and DAPI. Flow cytometry was performed on a BD Biosciences LSR II and analyzed with FlowJo (Tree Star Inc.). Only the larger POP-092S tumors yielded sufficient cell numbers for analysis.
F-FAZA-PET imaging and analysis
Hypoxia was assessed using µPET imaging of the hypoxia tracer Mice affected by gastro-intestinal toxicity (less than 5%) were excluded from the study. Tumor growth was monitored 3 times a week by caliper measurements.
Ex-vivo clonogenic assays
Mice bearing 200mm 3 HCT116 tumors, established by subcutaneous injection of 2x10 6 cells, were irradiated without anesthesia using a Gammacell. To create completely hypoxic tumors, one group of mice was sacrificed 5 minutes prior to irradiation, while the other group was sacrificed immediately following irradiation. Tumors were excised, dissociated, and colonyforming assays were performed, correcting for viability using trypan-blue exclusion. Table   S1 , including the use of metformin or other oral hypoglycemic drugs (e.g. sulfonylureas, thiazolidinediones, meglitinide) and/or insulin. The total radiotherapy dose was escalated over the period of accrual in a series of separate phase I/II studies as previously published (19) . The median radiation dose for the entire cohort was equivalent to 78Gy in 2Gy fractions. Patients were followed at 6 monthly intervals after completing treatment with clinical examination and prostate specific antigen (PSA).
Patient cohort and treatment characteristics
Statistical analysis
For studies in vitro or in experimental tumor models, two-sided t-tests or log-rank tests were used to assess statistical significance. For clinical data, the primary outcome was biochemical relapse free rate (bRFR) following the start of radiotherapy. Biochemical relapse was defined by the Phoenix criteria as a post-treatment PSA nadir plus 2 ng/ml or treatment of salvage hormones due to a rising PSA as previously described (19) . Patients who did not experience a biochemical relapse by their last known PSA date were considered censored. A Cox proportional-hazards model was used to determine whether metformin use influenced biochemical failure after RT independent of standard clinical prognostic factors. The proportional hazards assumption was checked for each variable by looking at the Schoenfeld residuals. As the proportional hazards assumption was found to be violated for metformin use, a Clinic website) (20) . Missing values of covariates were excluded. Covariate balance of the resulting cohort was assessed by ensuring all standardized differences were less than 10 (21).
Results
We measured oxygen consumption rates in vitro in the presence and absence of metformin in prostate carcinoma (LNCaP), head and neck squamous cell carcinoma (SCC-74B) and colorectal adenocarcinoma (HCT116 and POP-092S) cells. Metformin caused a significant dose-and time-dependent decrease in oxygen consumption in all cell lines (Fig.1A) . Substantial differences were observed across the lines in terms of both metformin sensitivity and response kinetics (Fig.1B) 
metformin typically achieved in the plasma of diabetic patients (0.02mM) (Fig.1A, B) . To determine if metformin could also inhibit oxygen consumption in vivo, we injected mice bearing HCT116 xenografts with 100mg/kg metformin and measured oxygen consumption rates in multiple tumor pieces ex vivo. This acutely administered dose corresponds to 25% of the daily oral dose taken by diabetic patients (22) . Metformin-treated tumors demonstrated reduced rates of oxygen consumption compared to controls (Fig.1C -7% reduction, p=0.005 ). These data show that metformin can reduce oxygen consumption in vitro and in vivo at clinically relevant doses.
Since tumor hypoxia arises in large part from oxygen consumption, we determined if metformin could improve oxygen distribution in tumors. To this end, we first injected tumorbearing mice with the 2-nitroimidazole pimonidazole (pimo) which binds and labels hypoxic cells in the absence of oxygen. After pimo had cleared the bloodstream (2 hours), we injected 100mg/kg metformin or administered carbogen, followed by injection of a second 2-nitroimidazole, EF5, along with a perfusion marker, Hoechst. This strategy allows for detection of hypoxic tumor cells before and after the intervention, using antibodies specific for pimo and EF5. Using quantitative immunohistochemistry (IHC) (Fig.S1A) , we found that metformin substantially reduced hypoxia in HCT116 tumors. Figure 2A 
cells, as well as the EF5 to pimo intensity ratio (Fig.2B ) dropped upon treatment with metformin.
Similar results were observed in the POP-092S colon xenograft model (Fig.S1C, D ). There were no consistent changes in tumor perfusion upon metformin treatment as measured by Hoechst staining (data not shown).
IHC allows spatial analysis of the tumor microenvironment with single-cell resolution, but represents only a sub-region of the tumor. To probe the tumor microenvironment on a scale representative of the whole tumor, we dissociated POP-092S tumors and measured hypoxia before and after metformin treatment using flow cytometry. Similar to IHC results, the fraction of hypoxic (EF5+) cells dropped significantly following metformin treatment, reflecting widespread tumor reoxygenation (Fig.2C,D) . The same approach was undertaken for LNCaP xenografts. These tumors supported very low levels of hypoxia, allowing quantitative analysis of only 4. Among these, metformin resulted in a substantial drop in hypoxia following metformin treatment (Fig.S1E) . This robust response is consistent with the superior sensitivity of LNCaP cells to metformin (Fig.1B) , but firm conclusions cannot be drawn in light of the low numbers.
Finally, in SCC-74B xenografts we experienced a much increased inter-tumor variability compared to the other models, and no evidence of metformin-induced altered oxygenation (data not shown). Hence, 3 out of 4 tumor models provided data supporting a substantially reduced hypoxic fraction following metformin treatment.
Since non-invasive hypoxia imaging is entering clinical practice, we assessed whether this modality could also resolve metformin-induced changes in tumor oxygenation . Groups of mice bearing HCT116 tumors were injected with the positron-emitting 2-nitroimidazole FAZA-PET analysis demonstrated a significant (p=0.01) reduction in the hypoxic tumor volume after metformin treatment (Fig.2E) . Taken together, results presented in Figure 2 demonstrate that metformin improves oxygenation as assessed at both micro-and macroscopic levels.
To test if the reduction in tumor hypoxia in metformin treated animals was sufficient to improve RT response, we irradiated HCT116 xenografts with a sub-curative, single dose of 15Gy and measured the time required for tumors to reach 4 times the irradiated volume. As expected, a single dose of metformin alone did not alter tumor growth (Fig.3A,B) . However, metformin administrated 30 minutes prior to irradiation significantly increased tumor growth delay (log rank p=0.0003 in A and t-test p=0.004 in B). This increase in tumor response was not due to a change in cellular intrinsic radiosensitivity of oxygenated cells, since metformin treatment in vitro did not influence response (Fig.S2A) . To corroborate this conclusion, we assessed the colony-forming ability of tumor cells in vitro following irradiation in vivo. We irradiated half of the tumor-bearing mice immediately following cervical dislocation, which renders all tumor cells hypoxic regardless of oxygen consumption rates. Consistent with the proposed mechanism, we observed that metformin only potentiated radiation-induced cell death in tumors from live, air-breathing mice (Fig.S2B) . These results strongly suggest that metformin increases tumor radiation response in vivo by reducing the hypoxic tumor fraction.
We reasoned that if metformin causes increased tumor oxygenation and radiation response, diabetic patients taking metformin might have better outcomes following curative RT.
We had previously shown that the presence of intra-glandular hypoxia leads to early biochemical failure (based on biochemical relapse-free rate; bRFR) following RT for localized prostate cancer (2). We therefore determined whether metformin altered early biochemical failure in 504 men undergoing similar curative prostate cancer RT that had differential metformin use (see Within a multivariate model, metformin use and a metformin interaction-with-time term, were both used to determine an independent effect of metformin on bRFR (see Table 1 and Fig. 4) .
Consistent with the pre-clinical data, the use of metformin was a significant and independent factor reducing early biochemical relapse after RT (after correcting for clinical covariates). As a complementary statistical approach, we also assessed the independent prognostic role of metformin using a propensity-score, matched analysis of 172 patients (Fig. S3 ) in which 86 patients taking metformin were matched based on previously reported covariates to patients in a control group (yielding proper balance among all covariates). In this sub-analysis, the bRFR at 3 years for patients on metformin was 92% as compared to 81% in the control group (adjusted hazard ratio= 0.63; 95% CI: 0.32 -1.24, p = 0.06, stratified log-rank; see Figure S4 ). A cumulative incidence analysis considering deaths without prior biochemical recurrence to be competing risks (data not shown) confirmed these findings.
Taken together, our data suggest that metformin can provide a benefit to cancer patients treated with RT through its effects on reprogramming tumor metabolism and increasing tumor oxygenation. 
Discussion
Epidemiological and retrospective studies have suggested that metformin may act as a cancer prevention and/or therapeutic agent (23) . Two different mechanisms of anticancer activity have been proposed for metformin and other biguanides. The first is due to their ability to reduce circulating insulin levels, removing a potential growth-stimulating factor in cancer cells expressing the insulin receptor (23, 24) . The second is through direct effects on metabolic activity of cancer cells, resulting in activation AMPK and subsequent inhibition of mTOR activity (23) (24) (25) (26) . Here we propose a new mechanism for metformin with specific application to cancers treated with radiotherapy -the inhibition of oxygen consumption (16, 17) , with consequential re-oxygenation of radio-resistant hypoxic cells; this effect is independent of an effect on tumor cell radiosensitivity.
In addition to tumor hypoxia, intrinsic cellular radiation resistance and high proliferation rates limit the efficacy of RT. In the preclinical tumor model used here, we found no evidence that metformin affects intrinsic radiosensitivity. Some studies have reported that metformin can function as a cellular radiosensitizer (27) (28) (29) , but this is clearly cell-line dependent (30, 31) . Furthermore, it is uncertain whether metformin associated changes in radiosensitivity would offer any therapeutic ratio benefit, since the response of normal tissues to combined RTmetformin is currently unknown. Reports have suggested that in cell lines in which metformin increases radiosensitivity, continuous administration of metformin before and after radiation can increase tumor growth delay (26, 28, 30) . In these studies, it is difficult to attribute the effects of metformin to specific mechanism(s), since they may include alterations of radiosensitivity, and tumor cell proliferation. Metformin alone also affects tumor growth in this setting, rendering the possible additive versus synergistic effect with radiation unclear. Our xenograft study was 
designed to provide proof-of-principle that metformin improves radiation response specifically by the mechanism of increased tumor oxygenation in vivo. This was achieved by selecting a cell line that was not radiosensitized by metformin in vitro or in vivo (Fig.S2) , and by delivering a single dose of metformin prior to radiation that alone had no effects on xenograft growth.
Metformin treatment did also not alter blood glucose levels in the experimental animals (Fig.S5 ).
According to standard and FDA-recommended guidelines on dose-conversion between species (22), the single i.v. dose of 100mg/kg metformin in mice, that was used in all in vivo experiments here, corresponds to about 25% of the daily dose taken orally by diabetic patients (2000mg). Metformin is known to accumulate in some tissues, rendering the concentrations substantially higher than the steady-state plasma level (32) . Tissue accumulation is likely dependent on expression of plasma membrane organic cation transporters (OCT) and multidrug and toxin extrusion (MATE) proteins (15) . Ultimately, the efficacy of metformin to inhibit oxygen consumption will rely on the local concentration at the mitochondria, which may depend on other additional factors. These considerations combined with our data demonstrating 7% reduction in oxygen consumption rates in tumors upon metformin administration ( Figure 1C (33) . Hypoxia modifying agents have therefore been suggested to be particularly important during hypofractionated RT schedules (7, 34) . Metformin may thus have a specific role in prostate cancer, where hypofractionated RT schemes are increasingly used.
We observed that prostate cancer patients taking metformin had decreased early biochemical failure after RT. Although this effect cannot be directly attributed to reduced tumor hypoxia, it is consistent with the expected impact that an increase in tumor oxygenation would have. It is enticing that metformin improves rates of early biochemical relapse with very similar effect size and interaction with time as oxygen status itself in a similar patient cohort (2).
Importantly, early biochemical failure after RT (e.g. within 18 months) has been observed to be a surrogate of prostate-cancer specific lethality (35) and if metformin use specifically reduced this risk, it could lower prostate cancer specific mortality. Indeed, a recent retrospective study observed lower rates of biochemical relapse, distant metastasis, prostate cancer specific mortality and overall mortality after combined RT-metformin use (27) . In a large population-based 
